Cayuga Biotech
Cayuga Biotech is dedicated to harnessing the body's innate ability to halt bleeding and heal, addressing significant unmet needs in hemorrhage control and bleeding disorders through proprietary science and innovative solutions.
What We Do
An optimized formulation of polyphosphate designed to accelerate the body's healing response to injury by increasing the rate of activation of specific coagulation factors, resulting in faster clotting and better outcomes.
A discovery-stage, novel composition designed for inherited bleeding disorders.
Battlefield Resuscitation
Regenerative Medicine
Biologics
Key People
Chief Executive Officer
Founder, Chief Science Officer
Corporate and Business Affairs
Clinical Operations
Translational Medicine
Funded Projects
Cayuga Biotech Presents Clinical Data on Lead Product PolyP-SNP for Hemorrhage Contol
Cayuga Biotech has advanced a novel injectable clotting agent—polyP-SNP—that rapidly generates thrombin and promotes safe, targeted clotting. Promising results were presented at ISTH 2024, and a Phase 1 clinical trial is expected to begin by the end of the year.
News & Updates
Cayuga Biotech received recognition for its outstanding oral presentation at a prestigious symposium.
Cayuga Biotech is set to present its latest research findings at the upcoming ISBS meeting.
Cayuga Biotech will showcase its research at the ASH Annual Meeting.
Cayuga Biotech announced promising data regarding its PolyP-SNP complex in addressing battlefield hemorrhage.
Cayuga Biotech revealed data showing significant improvements in coagulation speed in life-threatening situations.
Cayuga Biotech took part in a panel discussion focused on women in biotech.